D'Genes and AELIP attending the conference "Gene therapy: a hope for the cure of childhood rare diseases"

Source:

organized by the CIMA

The Association for Rare Diseases D'Genes and the Association of Relatives and Affected Lipodystrophies (AELIP) attended the conference "Gene therapy: a hope for cure rare diseases of childhood" this week, a presentation of great interest to the associations of rare diseases that took place on September 28 at the Cultural Center of the hamlet of Murcia Churra.

This activity is part of the collaboration agreement signed between the Spanish Federation for Rare Diseases (ERDF) and the Center for Applied Medical Research of the University of Navarra (CIMA) to promote gene therapy research in rare diseases, and, among other issues, also it allows the development of information activities in this area.

The talk was attended as speakers with the delegate of ERDF Murcia, David Sanchez;

the director of the Gene Therapy area of ​​CIMA, Dr. Gloria Gonzalez;

and the director of CIMA Development, Javier Viñeta.

CIMA is a reference center in Spain in pre-clinical treatment of rare diseases by applying gene therapy.

noticia
D'Genes and AELIP attending the conference "Gene therapy: a hope for the cure of childhood rare diseases", Foto 1

Comment this news on Facebook

If you want to comment on this news to the administrators of Totana.net, fill out the form below:

Send notification Code: 2024426
The owner of the personal data, collected in this form, expressly authorizes Alamo Networks, S.L. to treat said data in a computerized way and to be able to incorporate it into your database. The user may exercise the rights of access, rectification, cancellation and opposition of their personal data, in the terms established by the LOPD, at the address set in C / Alamo 8, 30850, Totana (Murcia). For your convenience you can also exercise your rights by email at the address info@totana.net
This website uses cookies to facilitate and improve navigation. If you continue browsing, we consider that you accept its use. More information